The short version
GHRP-2 is a synthetic six-residue growth-hormone secretagogue also known as KP-102 or pralmorelin. It activates the growth hormone secretagogue receptor, now usually called the ghrelin receptor or GHS-R1a. Researchers have used it to study pituitary signaling, growth-hormone release, appetite, endocrine responses, and provocative testing for growth-hormone deficiency.
The evidence includes cell and animal experiments, small human pharmacology studies, and diagnostic-validation research. Japan has a product-specific approval for pralmorelin hydrochloride as an in-vivo diagnostic agent for evaluating growth-hormone secretory function. That approval does not establish a general therapeutic benefit, authorize U.S. use, or transfer to material sold by research suppliers.
GHRP-2 is not GHRP-6, hexarelin, ghrelin, or ipamorelin. A familiar alias, chromatographic purity result, or research-use-only label cannot establish that a supplier vial matches an approved product or the test article used in a published study.
Identity first: GHRP-2, KP-102, and pralmorelin
FDA's substance-registration system maps GHRP-2, KP-102, and pralmorelin to the same active molecular identity. The listed sequence is D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2. The nonstandard naphthylalanine residue, D-amino acids, and terminal amide are defining features rather than optional label details.
Pralmorelin hydrochloride is a salt form used in the Japanese diagnostic product. A supplier page that says only GHRP-2 does not, by itself, establish the counterion, hydration state, quantitative peptide content, or equivalence to that finished formulation. Those attributes need their own records.
GHRP-2 and GHRP-6 are related, not interchangeable
Both compounds are synthetic hexapeptide agonists used to investigate the ghrelin-receptor system, but their sequences and physicochemical properties differ. GHRP-2 contains a naphthylalanine residue; GHRP-6 has a different sequence containing two tryptophan residues. Expected masses, chromatographic behavior, impurity profiles, and reference standards therefore differ.
Older comparative experiments sometimes describe GHRP-2 as more potent than earlier secretagogues in a specific assay. Potency is assay-, species-, and endpoint-dependent. A result in cultured ovine pituitary cells cannot be converted into a universal ranking, and evidence for one peptide cannot authenticate the other.
Laboratory evidence: direct pituitary responses and pathway interaction
In primary cultured ovine pituitary cells, KP-102 increased growth-hormone secretion, and a second exposure produced a smaller response. Blocking the growth-hormone-releasing-factor receptor abolished the measured response in that system, suggesting interaction between the pathways under those experimental conditions.
Other pharmacology work reported direct growth-hormone release from cultured rat anterior pituitary cells. Together, these studies support biological activity at pituitary targets, but they do not reduce the mechanism to one universal pathway. Cell source, receptor expression, exposure pattern, and assay design can change the observed response.
Laboratory secretion is a mechanistic endpoint. It does not establish treatment effectiveness, long-term safety, or how a complex endocrine system will respond outside the experimental model.
Animal evidence: endocrine and feeding effects vary by model
Rat studies reported growth-hormone release after GHRP-2 and also measured ACTH and corticosterone responses. Repeated experiments examined growth-related endpoints and organ weights, but those outcomes were model-specific and do not demonstrate human clinical benefit.
Experiments in swine found growth-hormone responses after oral exposure and evidence of attenuation with repeated short-term exposure. Such work helped investigators study route-dependent pharmacology and responsiveness, but species differences in digestion, receptor biology, endocrine feedback, and experimental conditions limit translation.
Animal appetite and body-weight findings are likewise hypothesis-generating. They cannot support a general claim that GHRP-2 should be used to change human appetite, weight, body composition, or recovery.
Small human endocrine studies show acute biological activity
An early randomized comparison in eight healthy men measured growth-hormone responses after GHRP-2, growth-hormone-releasing hormone, and the combination. The combination produced a larger response than either challenge alone, supporting interaction between the two signaling systems.
A separate study in people with a mutation of the growth-hormone-releasing-hormone receptor found a small GHRP-2 response despite the impaired pathway, but the response was far lower than in controls. The authors interpreted this as evidence that intact GHRH signaling is not an absolute requirement, while still showing that the broader system materially affects the result.
These studies measured acute hormone concentrations in small, selected groups. They do not establish durable benefit, appropriate clinical use outside the studied context, or a complete safety profile.
Repeated exposure can produce a different response than a single challenge
In nine healthy young men studied over five days, the growth-hormone response became smaller across repeated GHRP-2 exposures, and insulin-like growth factor I did not increase. That finding matters because a single challenge result cannot automatically predict repeated-exposure biology.
The experiment was short and small, so it cannot resolve longer-term adaptation, uncommon adverse events, or outcomes in broader populations. It does show why claims based on one acute hormone peak should not be projected into sustained physiological effects.
Human appetite findings are narrow and short term
A crossover experiment in seven healthy men reported greater food intake during a GHRP-2 condition than during saline. The study was designed as a controlled investigation of ghrelin-related eating behavior, not as evidence for a therapeutic weight-change strategy.
A longer study in ten children with growth-hormone deficiency reported a transient increase in appetite in several participants without a statistically significant change in standardized body-mass index. The population, formulation, study purpose, and clinical oversight differ fundamentally from research-supplier material.
Food intake in a single meal and self-reported appetite over time are different endpoints. Neither establishes a predictable effect on long-term body weight or health.
Pediatric pharmacokinetics provide limited, product-specific information
A phase-I study in ten prepubertal children with short stature described GHRP-2 concentration-time behavior and linked exposure to growth-hormone measurements after a single experimental challenge. The small study helped characterize pharmacokinetics and pharmacodynamics under controlled conditions.
It was not a large efficacy or safety trial. Results from ten children cannot characterize uncommon harms, long-term outcomes, or equivalence across formulations. They also cannot be generalized to an unidentified supplier vial lacking a connected manufacturing and analytical record.
Diagnostic evidence is more developed than therapeutic evidence
A Japanese validation study compared GHRP-2 provocative testing in 77 healthy participants and 58 people classified as having growth-hormone deficiency by an insulin-tolerance test. The researchers reported separation between groups and evaluated reproducibility and diagnostic thresholds.
A later study in 71 Japanese patients with pituitary tumors compared GHRP-2, arginine, and insulin-tolerance testing. It reported useful sensitivity and specificity for severe adult growth-hormone deficiency while emphasizing that methods and criteria need adjustment for the tested population.
Diagnostic performance does not demonstrate that GHRP-2 treats growth-hormone deficiency or another condition. A provocative test is intended to produce a measurable response that helps answer a diagnostic question; it is not evidence of therapeutic benefit.
Japan's approval is product- and purpose-specific
Japan's Pharmaceuticals and Medical Devices Agency lists GHRP Kaken 100 Injection, containing pralmorelin hydrochloride, as a prescription diagnostic product. The current record describes its purpose as diagnosis of growth-hormone secretory deficiency. Japan's approval record identifies pralmorelin hydrochloride as an in-vivo diagnostic agent for examining growth-hormone secretory function.
That status belongs to a defined finished product, jurisdiction, formulation, labeling, and diagnostic use. It does not mean every material called GHRP-2 is approved, and it does not create a U.S. approval. It also should not be rewritten as a broad claim that GHRP-2 is clinically proven for growth, body composition, appetite, anti-aging, or recovery.
U.S. regulatory and compounding context
FDA enforcement correspondence states that GHRP-2 is not a component of an FDA-approved human drug. FDA also lists GHRP-2 for injectable and nasal compounding routes among bulk substances that may present significant safety risks under its 503B interim policy.
FDA cites potential immunogenicity from aggregation and peptide-related impurities, the complexity added by an unnatural amino acid, and serious adverse-event reports for which causality has not been established. These statements are regulatory and risk signals, not proof that every research lot is defective. They do reinforce why identity, aggregation, impurities, and intended use cannot be inferred from a purity headline.
What supplier documentation can establish
A useful identity record for GHRP-2 should connect the exact lot and sample to the defined sequence or pralmorelin identity, expected and observed mass information, stated salt or counterion, method, laboratory, and report date. A mass result can support identity; it does not quantify every component or prove clinical equivalence.
Chromatographic area percentage describes detected components under stated conditions. It is not automatically net peptide content. Water, counterions, residual solvents, aggregation, sterility, endotoxin, and stability require separate methods and conclusions.
The published literature answers what a characterized test article did in a particular experiment. Supplier documentation answers what was measured in a particular lot. Product approval answers what a regulator concluded about a particular finished product and use. These evidence categories should remain separate.
- Confirm the exact GHRP-2 or pralmorelin identity and sequence
- Match listing, vial, sample, lot, and report identifiers
- Check expected and observed mass rather than relying on a name alone
- Distinguish salt form, water, purity, and quantitative peptide content
- Treat aggregation, sterility, endotoxin, and stability as separate attributes
- Do not transfer Japanese finished-product approval to research material
Major unresolved questions
The literature does not provide a large, modern, product-specific therapeutic program establishing long-term benefit and risk for common online claims. Important gaps include repeated-exposure endocrine effects, metabolic consequences, immunogenicity, impurity characterization, population variability, and the relationship between acute hormone responses and meaningful outcomes.
Future research would be easier to interpret with prospectively registered protocols, larger samples, predefined clinical endpoints, transparent adverse-event reporting, validated test-article characterization, and direct replication. Until then, the strongest conclusions remain about acute pharmacology and a specific diagnostic application—not general therapy.
FAQ: Are GHRP-2 and pralmorelin the same compound?
Pralmorelin is the international nonproprietary name mapped to the GHRP-2 or KP-102 molecular identity. Finished products may use a specified salt form such as pralmorelin hydrochloride, so the complete form and formulation still matter.
FAQ: Is GHRP-2 the same as GHRP-6?
No. They are distinct synthetic hexapeptides with different sequences, expected masses, physicochemical properties, and study records. Evidence or analytical documentation for one cannot establish the identity or behavior of the other.
FAQ: Does Japan's diagnostic approval mean supplier GHRP-2 is approved?
No. The Japanese status applies to a named pralmorelin-hydrochloride finished product for a defined diagnostic purpose. It does not transfer to an online research vial, create U.S. approval, or establish a therapeutic indication.
Sources and further reading
Primary and standards-based sources used to frame this educational overview:
- FDA GSRS: pralmorelin, GHRP-2, and KP-102 identity record
- PubMed: KP-102 response in primary cultured ovine pituitary cells
- PubMed: pharmacological characteristics of KP-102 / GHRP-2
- PubMed: oral GHRP-2 and growth-hormone release in swine
- PubMed: GHRP-2 and GHRH responses in eight healthy adults
- PubMed: GHRP-2 response with mutated GHRH receptor
- PubMed: five-day response attenuation study
- PubMed: GHRP-2 food-intake experiment in seven healthy men
- PubMed: appetite and body-weight observations in children
- PubMed: pediatric GHRP-2 phase-I pharmacokinetics
- PubMed: diagnostic validation of GHRP-2 in adult growth-hormone deficiency
- PubMed: GHRP-2 and arginine tests compared with insulin-tolerance testing
- PMDA: current GHRP Kaken 100 Injection product record
- PMDA: pralmorelin hydrochloride diagnostic approval record
- FDA: bulk substances that may present significant safety risks in compounding
- FDA warning letter: U.S. approval and 503A context for GHRP-2
Explore related resources
Peptide Due Diligence Research Brief
Keep the evidence in view.
Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free field guide.